FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2586374151> ?p ?o ?g. }

• W2586374151 endingPage "845" @default.
• W2586374151 startingPage "838" @default.
• W2586374151 abstract "Since the prognosis of advanced biliary tract cancer ( aBTC ) still remains very poor, new therapeutic approaches, including immunotherapies, need to be developed. In the current study, we conducted an open‐label randomized phase II study to test whether low dose cyclophosphamide ( CPA ) could improve antigen‐specific immune responses and clinical efficacy of personalized peptide vaccination ( PPV ) in 49 previously treated aBTC patients. Patients with aBTC refractory to at least one regimen of chemotherapies were randomly assigned to receive PPV with low dose CPA (100 mg/day for 7 days before vaccination) ( PPV / CPA , n = 24) or PPV alone ( n = 25). A maximum of four HLA ‐matched peptides were selected based on the pre‐existing peptide‐specific IgG responses, followed by subcutaneous administration. T cell responses to the vaccinated peptides in the PPV / CPA arm tended to be greater than those in the PPV alone arm. The PPV / CPA arm showed significantly better progression‐free survival (median time: 6.1 vs 2.9 months; hazard ratio ( HR ): 0.427; P = 0.008) and overall survival (median time: 12.1 vs 5.9 months; HR : 0.376; P = 0.004), compared to the PPV alone arm. The PPV alone arm, but not the PPV / CPA arm, showed significant increase in plasma IL ‐6 after vaccinations, which might be associated with inhibition of antigen‐specific T cell responses. These results suggested that combined treatment with low dose CPA could provide clinical benefits in aBTC patients under PPV , possibly through prevention of IL ‐6‐mediated immune suppression. Further clinical studies would be recommended to clarify the clinical efficacy of PPV / CPA in aBTC patients." @default.
• W2586374151 created "2017-02-17" @default.
• W2586374151 creator A5000734437 @default.
• W2586374151 creator A5006133126 @default.
• W2586374151 creator A5015402391 @default.
• W2586374151 creator A5021998416 @default.
• W2586374151 creator A5022553058 @default.
• W2586374151 creator A5027714564 @default.
• W2586374151 creator A5034428180 @default.
• W2586374151 creator A5038228482 @default.
• W2586374151 creator A5039491865 @default.
• W2586374151 creator A5074960437 @default.
• W2586374151 creator A5082628144 @default.
• W2586374151 creator A5085962041 @default.
• W2586374151 date "2017-05-01" @default.
• W2586374151 modified "2023-10-18" @default.
• W2586374151 title "A randomized phase <scp>II</scp> trial of personalized peptide vaccine with low dose cyclophosphamide in biliary tract cancer" @default.
• W2586374151 cites W1589114640 @default.
• W2586374151 cites W1973091654 @default.
• W2586374151 cites W2011122139 @default.
• W2586374151 cites W2044835625 @default.
• W2586374151 cites W2052753304 @default.
• W2586374151 cites W2054563013 @default.
• W2586374151 cites W2078448383 @default.
• W2586374151 cites W2080140626 @default.
• W2586374151 cites W2082830752 @default.
• W2586374151 cites W2096322385 @default.
• W2586374151 cites W2106550415 @default.
• W2586374151 cites W2112337250 @default.
• W2586374151 cites W2117241294 @default.
• W2586374151 cites W2125697254 @default.
• W2586374151 cites W2129153120 @default.
• W2586374151 cites W2146646005 @default.
• W2586374151 cites W2151021631 @default.
• W2586374151 cites W2153725546 @default.
• W2586374151 cites W2162771736 @default.
• W2586374151 cites W2197167222 @default.
• W2586374151 cites W2200769448 @default.
• W2586374151 cites W2201582389 @default.
• W2586374151 cites W2230826027 @default.
• W2586374151 cites W2244825058 @default.
• W2586374151 cites W2344131021 @default.
• W2586374151 doi "https://doi.org/10.1111/cas.13193" @default.
• W2586374151 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5448649" @default.
• W2586374151 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28188670" @default.
• W2586374151 hasPublicationYear "2017" @default.
• W2586374151 type Work @default.
• W2586374151 sameAs 2586374151 @default.
• W2586374151 citedByCount "26" @default.
• W2586374151 countsByYear W25863741512017 @default.
• W2586374151 countsByYear W25863741512018 @default.
• W2586374151 countsByYear W25863741512019 @default.
• W2586374151 countsByYear W25863741512020 @default.
• W2586374151 countsByYear W25863741512021 @default.
• W2586374151 countsByYear W25863741512022 @default.
• W2586374151 countsByYear W25863741512023 @default.
• W2586374151 crossrefType "journal-article" @default.
• W2586374151 hasAuthorship W2586374151A5000734437 @default.
• W2586374151 hasAuthorship W2586374151A5006133126 @default.
• W2586374151 hasAuthorship W2586374151A5015402391 @default.
• W2586374151 hasAuthorship W2586374151A5021998416 @default.
• W2586374151 hasAuthorship W2586374151A5022553058 @default.
• W2586374151 hasAuthorship W2586374151A5027714564 @default.
• W2586374151 hasAuthorship W2586374151A5034428180 @default.
• W2586374151 hasAuthorship W2586374151A5038228482 @default.
• W2586374151 hasAuthorship W2586374151A5039491865 @default.
• W2586374151 hasAuthorship W2586374151A5074960437 @default.
• W2586374151 hasAuthorship W2586374151A5082628144 @default.
• W2586374151 hasAuthorship W2586374151A5085962041 @default.
• W2586374151 hasBestOaLocation W25863741511 @default.
• W2586374151 hasConcept C126322002 @default.
• W2586374151 hasConcept C143998085 @default.
• W2586374151 hasConcept C147483822 @default.
• W2586374151 hasConcept C195616568 @default.
• W2586374151 hasConcept C203014093 @default.
• W2586374151 hasConcept C207103383 @default.
• W2586374151 hasConcept C22070199 @default.
• W2586374151 hasConcept C2776694085 @default.
• W2586374151 hasConcept C2776755627 @default.
• W2586374151 hasConcept C2776789287 @default.
• W2586374151 hasConcept C2781413609 @default.
• W2586374151 hasConcept C44249647 @default.
• W2586374151 hasConcept C535046627 @default.
• W2586374151 hasConcept C71924100 @default.
• W2586374151 hasConcept C8891405 @default.
• W2586374151 hasConcept C90924648 @default.
• W2586374151 hasConceptScore W2586374151C126322002 @default.
• W2586374151 hasConceptScore W2586374151C143998085 @default.
• W2586374151 hasConceptScore W2586374151C147483822 @default.
• W2586374151 hasConceptScore W2586374151C195616568 @default.
• W2586374151 hasConceptScore W2586374151C203014093 @default.
• W2586374151 hasConceptScore W2586374151C207103383 @default.
• W2586374151 hasConceptScore W2586374151C22070199 @default.
• W2586374151 hasConceptScore W2586374151C2776694085 @default.
• W2586374151 hasConceptScore W2586374151C2776755627 @default.
• W2586374151 hasConceptScore W2586374151C2776789287 @default.
• W2586374151 hasConceptScore W2586374151C2781413609 @default.
• W2586374151 hasConceptScore W2586374151C44249647 @default.

• next